Evidence map›Paper›PMID 41623794›Full record

ArticleBioinformation2025

Evaluation of histomorphological changes in breast cancer following neoadjuvant therapy at a tertiary care centre, Jharkhand.

Chanchal Ashok, Arvind Kumar, Aditi Priya, Saurav Banerjee, Alimuddin Ansari, Sunil Mahto

Abstract read
In one paragraph

Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chanchal AshokDepartment of Pathology, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India.
Arvind KumarDepartment of Pathology, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India.
Aditi PriyaDepartment of Pathology, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India.
Saurav BanerjeeDepartment of Pathology, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India.
Alimuddin AnsariDepartment of Pathology, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India.
Sunil MahtoDepartment of Pathology, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer remains a major cause of cancer-related mortality among women worldwide, with treatment response prediction posing a persistent challenge. Neoadjuvant therapy (NAT) offers tumor downstaging and assessment of histopathological response. In this prospective study of 125 patients, NAT led to a significant reduction in tumor cellularity (82.4% ± 12.3% to 31.7% ± 18.9%, p < 0.001) and increased fibrosis (15.2% ± 8.7% to 48.6% ± 15.4%, p < 0.001). Pathological complete response (pCR) occurred in 32% of patients, with higher rates in triple-negative (42.1%) and HER2-positive (38.5%) subtypes. High post-NAT tumor-infiltrating lymphocytes correlated strongly with pCR (r = 0.67, p < 0.001). Thus, we show that NAT induces significant histomorphological changes, which can serve as key prognostic indicators for therapeutic response and patient outcomes.

Indexed as

Breast cancerchangeshistologicaltherapy

Identifiers

PMID41623794
PMCPMC12859266

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.